This trial tests a cream that might help repigment skin affected by vitiligo, used twice a day for up to 48 weeks.
- Nonsegmental Vitiligo with Genital Involvement
0 Primary · 6 Secondary · Reporting Duration: Week 24 and 48
Side Effects for
Awards & Highlights
1 Treatment Group
1 of 1
30 Total Participants · 1 Treatment Group
Primary Treatment: Ruxolitinib Cream · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has the FDA authorized Ruxolitinib Cream for therapeutic use?
"According to the assessments made by our team at Power, Ruxolitinib Cream was given a score of 2 on a scale from 1-3. This is because there are preliminary indications that it is safe but no data confirming its efficacy in this Phase 2 trial." - Anonymous Online Contributor
Are there still openings for research participants in this clinical trial?
"Affirmative. Clinicaltrials.gov reveals that this medical study, which was initially listed on April 11th 2023, is actively recruiting volunteers. A total of 30 patients are needed to be recruited across 13 seperate sites." - Anonymous Online Contributor
How many individuals have volunteered to partake in this experiment?
"This clinical trial necessitates 30 participants meeting the set of established inclusion criteria. Patients can join from either Vitiligo & Pigmentation Institute of Southern California in Los Angeles, Michigan or Hamzavi Dermatology in Fort Gratiot, Ohio." - Anonymous Online Contributor
In how many geographic locations is this trial taking place?
"13 sites across the United States of America are currently running this clinical trial. These locations include Los Angeles, Fort Gratiot and Mayfield with additional centres situated in other cities. To reduce travel demands for potential participants it is wise to select a nearby site." - Anonymous Online Contributor